BridgeBio Oncology Therapeutics, Inc.
BBOTDrugs in Pipeline
9
Phase 3 Programs
4
Upcoming Catalysts
2
Next Catalyst
Aug 2026
Market Overview
Stock performance and key metrics
2 upcoming, 0 past
acoramidis
Amyloidosis
Acoramidis (AG10)
Amyloid Cardiomyopathy, Transthyretin-Related
Encaleret
Autosomal Dominant Hypocalcemia (ADH)
Infigratinib 0.25 mg/kg/day
Achondroplasia
BBT-207
EGFR Mutant Advanced Non-Small Cell Lung Cancer
Infigratinib 0.016 mg/kg
Achondroplasia
AG10
Amyloid Cardiomyopathy
BBT-877
Idiopathic Pulmonary Fibrosis
Infigratinib is provided as a single dose of minitablets for oral administration
Achondroplasia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
acoramidis | Phase 3 | Amyloidosis | - | - |
Acoramidis (AG10) | Phase 3 | Amyloid Cardiomyopathy, Transthyretin-Related | - | - |
Encaleret | Phase 3 | Autosomal Dominant Hypocalcemia (ADH) | - | - |
Infigratinib 0.25 mg/kg/day | Phase 3 | Achondroplasia | - | - |
BBT-207 | Phase 2 | EGFR Mutant Advanced Non-Small Cell Lung Cancer | - | - |
Infigratinib 0.016 mg/kg | Phase 2 | Achondroplasia | - | - |
AG10 | Phase 2 | Amyloid Cardiomyopathy | - | - |
BBT-877 | Phase 2 | Idiopathic Pulmonary Fibrosis | - | - |
Infigratinib is provided as a single dose of minitablets for oral administration | Phase 2 | Achondroplasia | - | - |